In the News | Friends of Cancer Research

You are here

In the News

December 2, 2019
More than 40 health and advocacy organizations penned a letter to lawmakers expressing support for Stephen Hahn to be the new FDA commissioner and calling for a swift confirmation. The groups sent... Read more
December 1, 2019
Executive Summary Rigorous planning and a multidisciplinary team including database experts and healthcare specialists with local knowledge are vital to effective real-world evidence, white paper... Read more
November 25, 2019
Friends of Cancer Research (Friends) recently announced the launch of its latest project, ctMoniTR. This pilot project will aim to harmonize the use of circulating tumor DNA (ctDNA) to monitor... Read more
November 25, 2019
On November 20, 2019, Stephen Hahn, MD, President Trump’s nominee to be the next Commissioner of the U.S. Food and Drug Administration (FDA), appeared before the Senate Health, Education, Labor, and... Read more
November 25, 2019
Tumor mutational burden (TMB) has generated interest as a potential biomarker of response to immunotherapy and has already been examined in the context of several lung cancer trials to gauge its... Read more
November 20, 2019
Washington, DC – November 20, 2019 – Today, Dr. Stephen Hahn, President Trump’s nominee to be the next Commissioner of the U.S. Food and Drug Administration (FDA), appeared before the Senate Health,... Read more
November 12, 2019
New Project Aims to Harmonize ctDNA for Monitoring Treatment Response   Washington, DC – November 12, 2019 – Today, Friends of Cancer Research (Friends) announced the launch of its latest project,... Read more
November 12, 2019
The US Food and Drug Administration (FDA) may expand a pilot project that allows for simultaneous drug approval decisions from US, Canadian and Australian regulators to include Singapore and... Read more
October 30, 2019
The number of expedited FDA approvals for cancer drugs that are based on surrogate end points is increasing, leading many to search for new ways to uncover efficacy and safety data to justify the... Read more

Pages